Syncona NAV grows in Q3
8th Feb 2024 09:04
(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.
Read moreSyncona net asset value falls, co-founder steps down
16th Nov 2023 08:44
(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.
Read moreSyncona shares slump as Novartis ends eye treatment development
11th Sep 2023 15:42
(Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.
Read moreSyncona reports slight dip in net assets
10th Aug 2023 08:34
(Sharecast News) - Healthcare investor Syncona reported a slight dip in net assets in its quarterly update on Thursday, to £1.24bn, down from £1.26bn at the end of March.
Read moreSyncona annual NAV falls in tough macro conditions
15th Jun 2023 07:39
(Sharecast News) - Health investor Syncona reported a fall in annual net asset value, driven by falls in its listed holdings and the partial write-down of neurological gene therapy company SwanBio, partially offset by foreign exchange tailwinds and uplifts elsewhere in its portfolio.
Read moreSyncona launches retinal disease-focussed Beacon Therapeutics
12th Jun 2023 07:51
(Sharecast News) - Healthcare company developer and investor Syncona announced the launch of Beacon Therapeutics on Monday.
Read moreSyncona said direct exposure to SVB 'de minimis'
13th Mar 2023 07:55
(Sharecast News) - Life sciences investor Syncona said it had a minimal exposure to the collapsed Silicon Valley Bank.
Read moreSyncona NAV falls in Q3
7th Feb 2023 07:16
(Sharecast News) - Healthcare company Syncona said on Tuesday that net assets had fallen in the three months ended 31 December, principally due to the declining value of its quoted holdings and foreign exchange fluctuations.
Read moreSyncona investee Autolus sells more American shares
22nd Dec 2022 08:04
(Sharecast News) - Life science-focussed healthcare company Syncona said on Thursday that its portfolio company Autolus Therapeutics had announced that the underwriters of its public offering of American depositary shares (ADSs), which closed on 13 December, had partially exercised their option to purchase an additional 6,927,102 ADSs.
Read moreSyncona's Autolus leukemia treatment meets trial endpoint
9th Dec 2022 07:21
(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.
Read moreSyncona makes 'positive' operational and clinical progress in H1
17th Nov 2022 08:16
(Sharecast News) - Healthcare company Syncona said on Thursday that it had delivered "positive operational and clinical progress" across its portfolio against a challenging macro backdrop in the six months ended 30 September.
Read moreSyncona to buy US biotech AGTC for $23.5m
24th Oct 2022 07:42
(Sharecast News) - Healthcare group Syncona said on Monday that it has agreed to buy US biotechnology firm Applied Genetic Technologies Corporation (AGTC) for around $23.5m, or $0.34 per share, in cash.
Read moreSyncona confident after Q1 market volatility
16th Aug 2022 10:06
(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.
Read moreSyncona reports flat year-end net assets
16th Jun 2022 07:27
(Sharecast News) - Healthcare investment company Syncona reported flat year-end net assets of £1.31bn in its final results on Thursday.
Read moreSyncona takes part in oversubscribed funding round for OMass
28th Apr 2022 08:59
(Sharecast News) - Syncona committed further funding for rare-disease specialist OMass Therapeutics alongside a syndicate of investors which included a unit of French drug giant Sanofi.
Read more